Federal Right to Try
Where Is It Going
Bibliographic Data
| ID | 20335805 |
|---|---|
| Authors | Kelly McBride Folkers (0000-0002-4912-2338), Kelly Folkers, Carolyn Riley Chapman (0000-0002-8793-6412), Carolyn Chapman, Barbara K Redman (0000-0001-5119-9898), Barbara Redman |
| Year | 2019 |
| Volume | 49 |
| Issue | 2 |
| Pages | 26-36 |
| Publication date | 2019-03-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | The Hastings Center Report (JOURNAL) |
| Journal identifiers | ISSN: 0093-0334 • E-ISSN: 1552-146X |
| Publisher | Wiley (PUBLISHER • GB) |
| DOI | 10.1002/hast.990 |
| PMID | 30998281 |
| OpenAlex | W2939140384 |
| Language | EN |
| Citations received | 3 |
| References cited | 14 |
Policy‐makers, bioethicists, and patient advocates have been engaged in a fierce battle about the merits and potential harms of a federal right‐to‐try law. This debate about access to investigational medical products has raised profound questions about the limits of patient autonomy, appropriate government regulation, medical paternalism, and political rhetoric. For example, do patients have a right to access investigational therapies, as the right‐to‐try movement asserts? What is government’s proper role in regulating and facilitating access to drugs that are still in development? In this review, we analyze the history of the right‐to‐try movement, review the arguments put forth by supporters and opponents of the legislation, and consider the movement’s consequences. Two possible scenarios may emerge. One is that the right‐to‐try pathway may fail to meaningfully increase patient access to investigational products. Alternatively, certain companies may attempt to rely on the federal right‐to‐try legislation to sell investigational products, taking advantage of the provision that allows for direct costs, as there is currently no clear mechanism for enforcement or monitoring of cost calculations
Autonomy · Battle · Business · Economics · Enforcement · Government (linguistics) · Law and economics · Legislation · Paternalism · Political science · Politics · Public relations · Right to know · Biomedical Ethics and Regulation · Ethics in Clinical Research · Health Systems, Economic Evaluations, Quality of Life · Law
Political and Organizational Influences in the Side Effects of FDA Approved Drugs
Should the governance of individual treatment attempts (“Individuelle Heilversuche”) include praxis evaluation? Results from qualitative stakeholder interviews
The Critical Role of Medical Institutions in Expanding Access to Investigational Interventions
| Citations per year | 0.43 |
|---|---|
| Citation span | 2019 - 2026 (8) |
| Highly cited | No |